Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Download Data

Monte Rosa Therapeutics Inc Return on Assets (ROA) 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Monte Rosa Therapeutics Inc Return on Assets (ROA) 5 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Return on assets (ROA) measures the profitability of a company relative to its total assets. It is calculated by dividing the net income by the total assets. This ratio indicates how effectively a company utilizes its assets to generate profits. A higher ROA suggests a more efficient use of assets and indicates better profitability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Monte Rosa Therapeutics Inc Return on Assets (ROA) for the Trailing 12 Months (TTM) ending March 31, 2023 was -8.13%, a -39.24% change year over year.
Monte Rosa Therapeutics Inc Return on Assets (ROA) for the Trailing 12 Months (TTM) ending March 31, 2022 was -5.84%, a 74.94% change year over year.
Monte Rosa Therapeutics Inc Return on Assets (ROA) for the Trailing 12 Months (TTM) ending March 31, 2021 was -23.30%.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends